{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:38:33Z","timestamp":1792013913383,"version":"4.4.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Beh\u00e7et\u2019s syndrome (BS) is a chronic form of relapsing multisystem vasculitis, characterized by recurrent oral and genital ulcers. Intestinal BS is a special type of BS. Volcano-shaped ulcers in the ileocecum are a typical finding of intestinal BS, and punched-out ulcers can be observed in the intestine or esophagus. At present, there is no recognized radical treatment for intestinal BS. Glucocorticoids and immunosuppressants are currently the main drugs used to improve the condition. Although it has been reported that monoclonal anti-TNF antibodies may be effective for some refractory intestinal BS, further randomized, prospective trials are necessary to confirm these findings. Some patients are restricted from using biological agents because of serious allergic reactions of drugs, inconvenient drug injections or the impact of the novel coronavirus epidemic. If endoscopic remission (endoscopic healing) is not achieved for a prolonged period of time, serious complications, such as perforation, fistula formation, and gastrointestinal bleeding can be induced. Therefore, it is necessary to develop new treatment methods for controlling disease progression. We reviewed the relevant literature, combined with the analysis of the correlation between the pathogenesis of BS and the mechanism of Janus kinase (JAK) inhibition, and considered that tofacitinib (TOF) may be effective for managing refractory intestinal BS. We report for the first time that four patients with severe refractory intestinal BS were successfully treated with TOF. We hope to provide valuable information on JAK inhibitors as potential therapeutic targets for the treatment of severe refractory intestinal BS.<\/jats:p>","DOI":"10.3389\/fimmu.2022.981502","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T08:11:37Z","timestamp":1663229497000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Case report: Refractory intestinal Beh\u00e7et\u2019s syndrome successfully treated with tofacitinib: A report of four cases"],"prefix":"10.3389","volume":"13","author":[{"given":"Na","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaokun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12107","article-title":"The international criteria for beh\u00e7et\u2019s disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"Update of the EULAR recommendations for the management of beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00535-020-01690-y","article-title":"Evidence-based diagnosis and clinical practice guidelines for intestinal beh\u00e7et\u2019s disease 2020 edited by intractable diseases, the health and labour sciences research grants","volume":"55","author":"Watanabe","year":"2020","journal-title":"J Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.11.026","article-title":"New insights into the pathogenesis of beh\u00e7et\u2019s disease","volume":"11","author":"De Chambrun","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2014.64","article-title":"Activation of the JAK\/STAT pathway in beh\u00e7et\u2019s disease","volume":"16","author":"Tulunay","year":"2015","journal-title":"Genes Immun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory beh\u00e7et\u2019s syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1673-8705.2020.02.005","article-title":"Tofacitinib for the treatment of refractory vascular beh\u00e7et\u2019s disease","volume":"14","author":"Liu","year":"2020","journal-title":"Chin J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219810","article-title":"Correspondence on \u2018A pilot study of tofacitinib for refractory beh\u00e7et\u2019s syndrome\u2019","author":"Zou","year":"2021","journal-title":"Ann Rheu Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1673-8705.2020.04.005","article-title":"Diagnostic value of gastroenteroscopy in intestinal beh\u00e7et\u2019s syndrome without gastrointestinal symptoms","volume":"14","author":"Tian","year":"2020","journal-title":"Chin J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2018.08.010","article-title":"Update on the epidemiology, risk factors and disease outcomes of beh\u00e7et\u2019s disease","volume":"32","author":"Akkoc","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel329","article-title":"Autoimmunity vs autoinflammation in beh\u00e7et\u2019s disease: Do we oversimplify a complex disorder","volume":"45","author":"Direskeneli","year":"2006","journal-title":"Rheumatology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et\u2019s disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nrrheum.2016.107","article-title":"Vasculitis syndromes: 16S RNA sequencing sheds light on beh\u00e7et disease","volume":"12","author":"Barranco","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"Revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15754","article-title":"The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal behcet\u2019s disease, a systematic review and meta-analysis","volume":"37","author":"Zhang","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03198.x","article-title":"Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal beh\u00e7et\u2019s disease","volume":"95","author":"Naganuma","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0872-4","article-title":"The 2nd edition of consensus statements for the diagnosis and management of intestinal beh\u00e7et\u2019s disease: Indication of anti-TNF\u03b1 monoclonal antibodies","volume":"49","author":"Hisamatsu","year":"2014","journal-title":"J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3349\/ymj.2016.57.1.22","article-title":"Intestinal beh\u00e7et\u2019s disease: A true inflammatory bowel disease or merely an intestinal complication of systemic vasculitis","volume":"57","author":"Kim","year":"2016","journal-title":"Yonsei Med J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21313","article-title":"Development, validation, and responsiveness of a novel disease activity index for intestinal beh\u00e7et\u2019s disease","volume":"17","author":"Cheon","year":"2011","journal-title":"Inflammation Bowel Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e31828f19c9","article-title":"Efficacy of infliximab in intestinal beh\u00e7et\u2019s disease: A Korean multicenter retrospective study","volume":"19","author":"Lee","year":"2013","journal-title":"Inflammation Bowel Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2020.00013","article-title":"Long-term safety and effectiveness of adalimumab in 462 patients with intestinal beh\u00e7et\u2019s disease: Results from a large real-world observational study","volume":"19","author":"Suzuki","year":"2021","journal-title":"Intest Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/4246965","article-title":"Gene expression profiling in behcet\u2019s disease indicates an autoimmune component in the pathogenesis of the disease and opens new avenues for targeted therapy","volume":"2018","author":"Puccetti","year":"2018","journal-title":"J Immunol Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: Prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ng.625","article-title":"Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with beh\u00e7et\u2019s disease","volume":"42","author":"Remmers","year":"2010","journal-title":"Nat Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.981502\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T08:11:42Z","timestamp":1663229502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.981502\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2022.981502"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.981502","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"article-number":"981502"}}